2 Sep 2008 07:00
FULCRUM PHARMA PLC
("the Company")
Appointment of Non-executive Director and Chairman Designate
The Board of Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, is pleased to announce that Grahame Cook has joined the board as a Non-executive Director and Chairman designate. It is planned that Sir Charles George will retire as Chairman and from the Board at the Annual General Meeting in December 2008.
Commenting on these changes to the Board, Dr Frank Armstrong, CEO of Fulcrum Pharma, said, "I would like to thank Sir Charles for his 8 years of leadership of the Board of Fulcrum Pharma. Sir Charles has been a dedicated and involved Chairman who has given great service to the Company. Looking forward, I am delighted to welcome Grahame Cook to the Board in the role of Chairman designate. As we look to grow and develop the business Grahame's background and skills will be invaluable."
Commenting on his appointment Mr. Cook said, "I am pleased to join the Board of Fulcrum Pharma at an exciting time of change for the company and the Pharma and Biotechnology industry as a whole. I am convinced of the opportunity Fulcrum Pharma has to become a substantial professional services company."
Mr. Cook, aged 50, a chartered accountant, has held a number of senior executive positions including, most recently his role as Chief Executive at WestLB Panmure, until 2003, where he was responsible for all global functions and the expansion and development of WestLB Panmure's business. Prior to this he spent three years at UBS as a managing director where he was on the Global Investment Banking Management Committee. He was also a director of Barclays de Zoete Wedd. He was a founding member of the London Stock Exchange techMARK Advisory Council and currently holds various other non-executive positions including Antisoma PLC, Sinclair Pharma Plc and Minoan Group plc.
For further information, please contact:
| Fulcrum Pharma PLC | |
| Dr Frank M Armstrong, Chief Executive | Tel: 07508 010912 |
| Seymour Pierce | |
| Jonathan Wright | Tel: 0207 107 8000 |
In accordance with Schedule 2(g) of the AIM Rules for Companies the following information in relation to the appointment of Grahame Cook to the Board of Fulcrum is disclosed:
Current Directorships/Partnerships:
Trigen Holdings Ltd
Trigen Limited
Sinclair Pharma plc
Morphogenesis Inc.
Roundpoint Inc.
Australian Vineyards Direct Limited
Minoan Group Plc
Antisoma plc
Kinnerton Street Freeholds Limited
T&JK Holdings Limited
T&JK Estates Limited
KS Halkins LLP
Previous Directorships/Partnerships:
West LB Basinghall Limited
Rectory Nominees Limited
BIW plc
BIW Technoogies Limited
West Private Equity Limited
Lyceum Capital Limited
Equity Holdings Limited
St. Michael Nominees Limited
Parish Nominees Limited
Ryes Capital LLP
Equity Development Limited.
There is no further information to be disclosed in respect of Schedule 2(g) of the AIM Rules.
About Fulcrum Pharma plc
Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones. Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval
Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.
FUL.L (FUL)